Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

Nature of Relevant Financial Relationship Last Name Role in Activity Commercial Interest What Was Received For What Role  AbbVie, Inc., Prometheus  Honoraria  Consultant Laboratories Inc. Boland Planning Committee  , Inc., Takeda  Grant  Research Pharmaceutical Company, Ltd.  Textbook  Lippincott, Oxford University Publications Press  Royalties  Advisory Board and  Elsevier Bonakdar Faculty  Honoria Editorial contributor  Thorne Research Inc.,  Consulting Fee  PracticeUpdate.com Metagenics, Inc., American Consultant in the Specialty Health area of pain  Takeda Pharmaceutical Company, Cohen Faculty  Honoraria  Speaker Fee Ltd.  Advisory Committee,  AbbVie, Inc.  Honoraria Speaker’s Bureau

Collins Faculty  Janssen Pharmaceutica  Honoraria  Speaker’s Bureau

 Takeda Pharmaceutical Company,  Honoraria  Advisory Committee Ltd.  AbbVie, Inc., Salix Coyle Planning Committee  Honoraria  Speaker’s Bureau Pharmaceuticals  Buhlmann Laboratories AG,  Research  Investigator Polymedco CDP, LLC  Consultant,  , Inc.  Grant Dulai Planning Committee Investigator  AbbVie, Inc., Janssen  Consultant, Pharmaceutica, Takeda  Grant, Honorarium Investigator Pharmaceuticals USA, Inc.  AbbVie, Inc., Inc., AstraZeneca, Atlantic Pharmaceuticals Ltd., Boehringer‐ Ingelheim, Celgene Corporation Corporation, Group Plc, Inc., Hoffmann‐La Roche Ltd., Inc.,  Research Grant  Research Support GlaxoSmithKline (GSK), Janssen Research & Development LLC., MedImmune Ltd., Pfizer Inc., Feagan Faculty Receptos Inc., Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, UCB  Abbott/AbbVie, Inc., Inc., Akebia Therapeutics, , Amgen, Applied Molecular Transport Inc.,  Honoraria  Consultant Aptevo Therapeutics, Astra , Atlantic Pharma, Avir Pharma, Idec, BiomX, Inc.‐ S:\Clinical Research Services\Conference Folder\Conferences\Annual Courses\IBD 208\2019\CME\01 Faculty Disclosure Grid.docx

Israel, Boehringer‐Ingelheim, Bristol‐Myers Squibb, Calypso Biotech, Celgene Corporation, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, Galen/Atlantica, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, Intact Therapeutics, Janssen Pharmaceutica, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestles, Nextbiotix, Novonordisk, ParImmune, Parvus Therapeutics Inc., Pfizer, Inc., Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Qu Biologics, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., Zyngenia  Abbott, AbbVie, Inc., Janssen Pharmaceutica, Lilly, Takeda,  Honoraria  Speaker’s Bureau Tillotts, UCB Pharma  Abbott, AbbVie, Inc.., Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer‐Ingelheim, Bristol‐ Myers Squibb, Celgene Corporation, Centocor Inc., Elan/Biogen, Galapagos,  Honoraria  Advisory Board Genentech/Roche, Janssen Pharmaceutica, Merck, Nestles, Novartis, Novonordisk, Pfizer, Inc., Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, UCB Pharma  Travel  Senior Scientific  Robarts Clinical Trials Inc. Reimbursement Officer  AbbVie, Inc., Bayer HealthCare  Advisory Board Pharmaceuticals, Merck, Salix  Honoraria Consultant, Research, Pharmaceuticals Speaker’s Bureau  Advisory Board,  Gilead Sciences, Inc.  Honoraria Consultant, Speaker’s Bureau  AbbVie, Inc., Bristol‐Myers Squibb, Conatus  Honoraria  Speakers Bureau Frenette Faculty Pharmaceuticals, Merck, ,  Dova Pharmaceuticals, Intercept  Advisory Board,  Honoraria Pharmaceuticals Speaker’s Bureau  GENFIT SA,  Honoraria  Research Support Pharmaceuticals  Gilead Sciences, Inc., Intercept Pharmaceutical, Wako  Honoraria  Advisory Board Diagnostics

Gerich Faculty  None  N/A  N/A

 Advisory Board,  AbbVie, Inc.  Honoraria Speaker’s Bureau Ha Faculty  Janssen Pharmaceutica, Pfizer,  Honoraria  Advisory Board Inc., Takeda Pharmaceutica, Inc.  AbbVie, Inc., Takeda  Honoraria  Speaker’s Bureau Pharmaceuticals USA, Inc. Konijeti  AbbVie, Inc., Janssen Pharmaceutica, Pfizer, Inc.,  Honoraria  Advisory Board Takeda Pharmaceutical USA, Inc.  AbbVie, Inc., Allergan, Bemis Company, Inc., Gilead Sciences, Inc., Janssen Pharmaceitica,  Honorarium  Consultant Mahadevan Faculty Takeda Pharmaceutical Company, Ltd.  Celgene Corporation Corporation,  Grant  Research Pfizer, Inc.  AbbVie, Inc., Janssen Biotech, Inc., Merck & Co. Inc., Pfizer,  Consulting Fee  Advisory Board Takeda Pharmaceutical Company, Osterman Faculty Ltd.

 UCB  Grant  Research

 Amgen, Inc., Genentech, Inc., Janssen Biotech, Inc., Pfizer, Inc.,  Grant  Consultant Prometheus Laboratories, Inc.  AbbVie, Inc., Genetics, Salix Pharmaceuticals, Inc., Shire  Honorarium  Consultant Plc, Takeda Pharmaceutical Company, Ltd., UCB Inc.  Atlantic Healthcare Ltd, Amgen Inc., Celgene Corporation, , Genentech, Inc., Gilead Sciences, AbbVie, Inc.,  Grant  Research Janssen Biotech, Inc., Takeda Pharmaceutical Company, Ltd, Receptos, Inc.  AbbVie, Inc., Inc., Allergan, Amgen Inc., Arena Pharmaceuticals, Inc., Avexegen Therapeutics, Inc., BeiGene, Sandborn Planning Committee Boehringer Ingelheim, Celgene Corporation, Celltrion, Conatus Pharmaceuticals, Cosmo Pharmaceuticals, Escalier Biosciences, Inc., Ferring Pharmaceuticals, Forbion, Genentech, Inc., Gilead Sciences, Gossamer Bio, Incyte  Consultant Fee  Consultant Corporation, Janssen Pharmaceutica, Kyowa Kirin Pharmaceutical Research, Inc., Landos Biopharma, Inc., Eli Lilly and Company, Oppilan Pharma Ltd., Otsuka Pharmaceutical, Prizer, Precision IBD, Progenity, Prometheus Laboratories, Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust,

HART), Seres Therapeutics, Inc., Shire Plc, Sienna , Sigmoid Biotechnologies Ltd., Sterna Biologicals GmbH & Co. KG, Sublimity Therapeutics Limited, Takeda Pharmaceutical Company, Theravance Biopharma, TiGenix, Tillotts Pharma AG, UCB Pharma, Ventyx Biosciences Ltd., Vimalan Biosciences, Inc., Vivelix Pharmaceuticals Ltd  BeiGene, Escalier Biosciences, Inc., Gossamer Bio, Oppilan Pharma, Ltd., Precision IBD,  Stock  Advisor Progenity, Ritter Pharmaceuticals, Ventyx Biosciences, Inc., Vimalan Biosciences, Inc.  Escalier Biosciences, Ophthotech,  Stock  Consultant Progenity (Spouse)  Oppilan Pharma, Precision IBD, Ltd., Ventyx Biosciences, Inc.,  Stock  Employee Vimalan Biosciences, Inc. (Spouse)

 AbbVie, Inc.  Grant  Research

Singh Planning Committee  Pfizer, Inc.  Honorarium  Grant Review

 Takeda Pharmaceutical Company  Honorarium  Consultant

Velayos Faculty  None  N/A  N/A

Whitmire Faculty  None  N/A  N/A

Worsey Planning Committee  Healthtrust  Honorarium  Research

Review of all CME CME Committee  None  N/A  N/A content Plan, manage, Scripps Conference implement, and  None  N/A  N/A Services & CME reconcile activity

Faculty Disclosure

Glossary of Terms

Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re‐selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant Financial Relationships ACCME focuses on financial relationships with commercial interests in the 12‐month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Conflict of Interest Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or service of a commercial interest with which he/she has a financial relationship.

S:\Clinical Research Services\Conference Folder\Conferences\Annual Courses\IBD 208\2019\CME\01 Faculty Disclosure Grid.docx